{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:16:34Z","timestamp":1791468994167,"version":"4.3.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.urolonc.2020.03.008","type":"journal-article","created":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T17:16:58Z","timestamp":1586539018000},"page":"684.e9-684.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1272-7154","authenticated-orcid":false,"given":"Alberto","family":"Martini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo Giovanni","family":"Falagario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Waingankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Daza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Julien","family":"Treacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Galsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Sfakianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6_suppl","key":"10.1016\/j.urolonc.2020.03.008_bib0001","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1200\/JCO.2018.36.6_suppl.407","article-title":"Results of POUT: a phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC)","volume":"36","author":"Birtle","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.03.008_bib0002","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.euf.2017.03.013","article-title":"Platinum-based neoadjuvant chemotherapy improves oncological outcomes in patients with locally advanced upper tract urothelial carcinoma","volume":"4","author":"Hosogoe","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"2","key":"10.1016\/j.urolonc.2020.03.008_bib0003","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000282755","article-title":"Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract","volume":"55","author":"Igawa","year":"1995","journal-title":"Urol Int"},{"issue":"12","key":"10.1016\/j.urolonc.2020.03.008_bib0004","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.28655","article-title":"Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma","volume":"120","author":"Porten","year":"2014","journal-title":"Cancer"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2020.03.008_bib0005","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS4585","article-title":"ECOG 8141: a prospective phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery for patients with high grade upper tract urothelial carcinoma","volume":"34","author":"Hoffman-Censits","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2020.03.008_bib0006","unstructured":"Group TEU-O, Centre for Human Drug Research N. Feasibility of neo-adjuvant versus adjuvant chemotherapy in upper tract urothelial carcinoma. https:\/\/ClinicalTrials.gov\/show\/NCT02969083; 2018."},{"issue":"2","key":"10.1016\/j.urolonc.2020.03.008_bib0007","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/1097-0142(19940115)73:2<499::AID-CNCR2820730241>3.0.CO;2-T","article-title":"The national cancer data base. A mechanism for assessment of patient care","volume":"73","author":"Steele","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2020.03.008_bib0008","doi-asserted-by":"crossref","DOI":"10.1111\/bju.14719","article-title":"Pathological downstaging as a novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinoma","author":"Martini","year":"2019","journal-title":"BJU Int"},{"issue":"18","key":"10.1016\/j.urolonc.2020.03.008_bib0009","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1002\/cncr.32169","article-title":"Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer","volume":"125","author":"Martini","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2020.03.008_bib0010","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.critrevonc.2019.01.019","article-title":"Effect of neoadjuvant chemotherapy on locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis","volume":"135","author":"Kim","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"60","key":"10.1016\/j.urolonc.2020.03.008_bib0011","doi-asserted-by":"crossref","first-page":"101500","DOI":"10.18632\/oncotarget.21551","article-title":"Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study","volume":"8","author":"Kubota","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.urolonc.2020.03.008_bib0012","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ucl.2017.12.011","article-title":"Perioperative immunotherapy in muscle-invasive bladder cancer and upper tract urothelial carcinoma","volume":"45","author":"Teo","year":"2018","journal-title":"Urol Clin North Am"},{"issue":"6","key":"10.1016\/j.urolonc.2020.03.008_bib0013","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","article-title":"Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration","volume":"115","author":"Margulis","year":"2009","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2020.03.008_bib0014","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11934-016-0595-1","article-title":"Complications following radical nephroureterectomy","volume":"17","author":"Raman","year":"2016","journal-title":"Curr Urol Rep"},{"issue":"6","key":"10.1016\/j.urolonc.2020.03.008_bib0015","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.juro.2017.12.062","article-title":"Neoadjuvant dose dense MVAC versus gemcitabine and cisplatin in patients with cT3-4aN0M0 bladder cancer treated with radical cystectomy","volume":"199","author":"Zargar","year":"2018","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.03.008_bib0016","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.juro.2012.05.079","article-title":"Urothelial carcinoma of the bladder and the upper tract: disparate twins","volume":"189","author":"Green","year":"2013","journal-title":"J Urol"},{"issue":"13","key":"10.1016\/j.urolonc.2020.03.008_bib0017","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2005.03.163","article-title":"Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma","volume":"23","author":"Catto","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.03.008_bib0018","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","article-title":"Genomic characterization of upper tract urothelial carcinoma","volume":"68","author":"Sfakianos","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.03.008_bib0019","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2014.03.003","article-title":"A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma","volume":"66","author":"Leow","year":"2014","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2020.03.008_bib0020","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/bju.14751","article-title":"Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy","volume":"124","author":"Zamboni","year":"2019","journal-title":"BJU Int"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920300922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920300922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:17:52Z","timestamp":1761041872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920300922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1078143920300922"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.03.008","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}